---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-000580"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:19:13.673747+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Galectin completes enrollment in NAVIGATE Phase 2b/3 belapectin study for NASH cirrhosis

## Summary
- 309 patients randomized to date; expects 325-340 total by early March 2023.
- Phase 2b portion studies belapectin 2 mg/kg and 4 mg/kg vs. placebo (1:1:1).
- Primary endpoint: primary prevention of esophageal varices in NASH cirrhosis with portal hypertension.
- Interim analysis results expected in Q4 2024 after 18-month treatment period.
- Study recruited patients across 14 countries and five continents.

## SEC filing metadata
- accession: 0001140361-23-000580
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036123000580/0001140361-23-000580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036123000580/brhc10046311_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-000580
- JSON: https://secwatch.observer/filing/0001140361-23-000580.json
- Plain text: https://secwatch.observer/filing/0001140361-23-000580.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.